AlphaValue/Baader Europe Reduces Merck KGaA's EPS Forecast on US Dollar Weakness

Published on 20/05/2025 at 08:48

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Merck KGaA

Merck KGaA Gets Conditional Approval To Market Ezmekly Drug in EU	07-18	DJ
Merck KGaA Gets EU Conditional Marketing Approval for Plexiform Neurofibroma Therapy	07-18	MT
Merck European Commission grants conditional approval of Ezmekly	07-18	RE
European share rise on tech, banks boost with focus on US trade negotiations	07-07	RE
Frankfurt Stocks Close: DAX Defies US Tariff Threats Ahead of Deadline	07-07	DP
Stifel Downgrades Merck KGaA to Sell, Cuts PT	07-07	MT
MERCK KGAA : bottom of the DAX, with Stifel downgrade	07-07
Frankfurt stock market opening: DAX rises slightly - US tariffs in focus	07-07	DP
Merck KGaA Shares Approach Yearly Low After Sell Recommendation	07-07	DP
Merck KGaA completed the acquisition of SpringWorks Therapeutics, Inc. from FMR LLC, The Vanguard Group, Inc. and BlackRock, Inc. and others.	07-01	CI
Merck Seals Largest Pharma Deal in Decades	07-01	DP
Germany's Merck KGaA Closes $3.4 Billion Purchase of US-based SpringWorks	07-01	MT
Merck completes acquisition of Springworks – explores further acquisitions	07-01	DP
MERCK KGAA : UBS reiterates its Buy rating	07-01	ZD
Merck: EMD Serono Presents Results On Efficacy And Safety Of Enpatoran	06-12	RE
China's Center for Drug Evaluation Accepts Merck KGaA's Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor	06-10	CI
Merck: FDA approves Enflonsia RSV vaccine	06-10
Merck KGaA's Application to Market Tumor Treatment Pimicotinib to Be Reviewed By China	06-10	DJ
Merck KGaA Wins Chinese Approval for Tenosynovial Giant Cell Tumor Treatment	06-10	MT
China's Center For Drug Evaluation Accepts Merck KGaA, Darmstadt, Germany's Application For Marketing Authorization Of Pimicotinib	06-10	RE
Health insurers in favor of cost containment for drug spending	06-03	DP
MERCK KGAA : JP Morgan reiterates its Buy rating	06-03	ZD
MERCK KGAA : Deutsche Bank maintains a Buy rating	05-30	ZD
Merck KGaA Says Cell Tumor Inhibitor Shows Promise in Late-Stage Trial	05-28	DJ
Bernstein lowers target for Merck KGaA - 'Market Perform'	05-27	DP